Parthenon LLC held its stake in shares of Mead Johnson Nutrition Co. (NYSE:MJN) during the second quarter, Holdings Channel reports. The fund owned 7,588 shares of the company’s stock at the end of the second quarter. Parthenon LLC’s holdings in Mead Johnson Nutrition were worth $689,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in MJN. Bank of Montreal Can bought a new stake in shares of Mead Johnson Nutrition during the second quarter worth approximately $101,332,000. NN Investment Partners Holdings N.V. bought a new stake in shares of Mead Johnson Nutrition during the first quarter worth approximately $52,905,000. UBS Asset Management Americas Inc. boosted its stake in shares of Mead Johnson Nutrition by 38.7% in the first quarter. UBS Asset Management Americas Inc. now owns 684,932 shares of the company’s stock worth $58,199,000 after buying an additional 190,967 shares during the period. PGGM Investments boosted its stake in shares of Mead Johnson Nutrition by 132.1% in the second quarter. PGGM Investments now owns 326,344 shares of the company’s stock worth $29,616,000 after buying an additional 185,748 shares during the period. Finally, Sensato Investors LLC bought a new stake in shares of Mead Johnson Nutrition during the first quarter worth approximately $13,841,000. 96.93% of the stock is owned by hedge funds and other institutional investors.

Mead Johnson Nutrition Co. (NYSE:MJN) traded up 1.80% during midday trading on Wednesday, hitting $78.14. The stock had a trading volume of 1,191,341 shares. The stock has a market capitalization of $14.43 billion, a PE ratio of 29.40 and a beta of 1.17. The stock’s 50-day moving average is $83.82 and its 200-day moving average is $84.78. Mead Johnson Nutrition Co. has a 1-year low of $65.53 and a 1-year high of $94.40.

Mead Johnson Nutrition (NYSE:MJN) last posted its quarterly earnings data on Thursday, July 28th. The company reported $0.88 EPS for the quarter, topping the Zacks’ consensus estimate of $0.78 by $0.10. The company had revenue of $941.50 million for the quarter, compared to analyst estimates of $967.25 million. Mead Johnson Nutrition had a negative return on equity of 194.30% and a net margin of 13.28%. The firm’s quarterly revenue was down 8.8% on a year-over-year basis. During the same period in the previous year, the firm earned $0.76 earnings per share. On average, equities research analysts anticipate that Mead Johnson Nutrition Co. will post $3.49 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Monday, October 3rd. Shareholders of record on Monday, September 19th will be issued a $0.4125 dividend. The ex-dividend date is Thursday, September 15th. This represents a $1.65 dividend on an annualized basis and a yield of 2.11%. Mead Johnson Nutrition’s payout ratio is currently 62.03%.

A number of analysts have recently commented on MJN shares. Zacks Investment Research cut Mead Johnson Nutrition from a “buy” rating to a “hold” rating in a research note on Monday, June 13th. Susquehanna reaffirmed a “hold” rating on shares of Mead Johnson Nutrition in a research note on Thursday, June 16th. Credit Suisse Group AG reaffirmed a “buy” rating and issued a $96.00 price target on shares of Mead Johnson Nutrition in a research note on Thursday, June 30th. Bank of America Corp. raised Mead Johnson Nutrition from an “underperform” rating to a “neutral” rating and set a $93.00 price target for the company in a research note on Wednesday, July 13th. Finally, Goldman Sachs Group Inc. reaffirmed a “neutral” rating and issued a $96.00 price target (up from $91.00) on shares of Mead Johnson Nutrition in a research note on Friday, July 15th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and six have issued a buy rating to the company. Mead Johnson Nutrition has a consensus rating of “Hold” and an average price target of $95.75.

In other Mead Johnson Nutrition news, SVP Graciela Monteagudo sold 45,873 shares of Mead Johnson Nutrition stock in a transaction that occurred on Friday, August 5th. The stock was sold at an average price of $87.64, for a total value of $4,020,309.72. Following the completion of the sale, the senior vice president now directly owns 13,800 shares in the company, valued at $1,209,432. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Kimberly A. Casiano sold 710 shares of Mead Johnson Nutrition stock in a transaction that occurred on Monday, August 15th. The stock was sold at an average price of $89.75, for a total value of $63,722.50. Following the completion of the sale, the director now owns 7,110 shares of the company’s stock, valued at $638,122.50. The disclosure for this sale can be found here. 0.50% of the stock is owned by company insiders.

About Mead Johnson Nutrition

Mead Johnson Nutrition Company (Mead Johnson) is a pediatric nutrition company. The Company manufactures, distributes and sells infant formulas, children’s nutrition and other nutritional products. The Company operates through three segments: Asia, North America/Europe and Latin America. Its product portfolio includes routine and specialty infant formulas, children’s milks and milk modifiers, dietary supplements for pregnant and breastfeeding mothers, pediatric vitamins, and products for pediatric metabolic disorders.

5 Day Chart for NYSE:MJN

Want to see what other hedge funds are holding MJN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mead Johnson Nutrition Co. (NYSE:MJN).

Receive News & Ratings for Mead Johnson Nutrition Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mead Johnson Nutrition Co. and related companies with Analyst Ratings Network's FREE daily email newsletter.